Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 4/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.54 |
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15995566 | 0.89 | SIGMAR1 (0.52) | DRD2DRD4SIGMAR1CCR2BACE1 | |
| SCHEMBL16305523 | 0.89 | SIGMAR1 (0.52) | DRD2DRD4SIGMAR1CCR2BACE1 | |
| SCHEMBL16293637 | 0.86 | BCHE (0.59) | DRD2DRD4SIGMAR1BACE1 | |
| SCHEMBL18880312 | 0.85 | BCHE (0.53) | DRD2DRD4SIGMAR1BACE1 | |
| SCHEMBL15636721 | 0.79 | SIGMAR1 (0.52) | DRD2DRD4SIGMAR1CCR2MCHR1 | |
| SCHEMBL18880282 | 0.74 | BACE1 (0.48) | BACE1 | |
| SCHEMBL15636850 | 0.73 | DRD4 (0.55) | DRD4SIGMAR1 | |
| SCHEMBL239527 | 0.73 | DRD4 (0.71) | DRD2DRD4SIGMAR1BACE1MCHR1 | |
| SCHEMBL239528 | 0.73 | DRD4 (0.71) | DRD2DRD4SIGMAR1BACE1MCHR1 | |
| SCHEMBL9972648 | 0.72 | CCR2 (0.87) | DRD2DRD4CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | claimed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | claimed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2961736-B1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-3170811-A1 | ETHYL PYRIDINE-4-CARBOXYLATE COMPOUND AS INHIBITOR OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650339-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9221801-B2 | Inhibitors of histone demethylases | EPITHERAPEUTICS APS (DK) | 2015-12-29 | — | — | US | disclosed |
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371214-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | DRD2 4072/4885DRD4 4105/4885SIGMAR1 2943/4885 |
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | DRD2 4072/4885DRD4 4105/4885SIGMAR1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.